期刊
KIDNEY INTERNATIONAL
卷 89, 期 6, 页码 1192-1203出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2016.01.033
关键词
biomarker; cell signaling; chronic kidney disease; cystinosin; end-stage kidney disease; rare kidney diseases
资金
- National Institutes of Health
- Raptor
- Alexion
- Hyperion
- University of Michigan
- Kidney Disease: Improving Global Outcomes (KDIGO)
- Cystinose Groep Nederland
- Cystinosis Foundation
- Cystinosis Research Network
- La Asociacion Mexicana de Cistinosis
- Orphan Europe
- Raptor Pharmaceuticals
Nephropathic cystinosis is an autosomal recessive metabolic, lifelong disease characterized by lysosomal cystine accumulation throughout the body that commonly presents in infancy with a renal Fanconi syndrome and, if untreated, leads to end-stage kidney disease (ESKD) in the later childhood years. The molecular basis is due to mutations in CTNS, the gene encoding for the lysosomal cystine-proton cotransporter, cystinosin. During adolescence and adulthood, extrarenal manifestations of cystinosis develop and require multidisciplinary care. Despite substantial improvement in prognosis due to cystine-depleting therapy with cysteamine, no cure of the disease is currently available. Kidney Disease: Improving Global Outcomes (KDIGO) convened a Controversies Conference on cystinosis to review the state-of-the-art knowledge and to address areas of controversies in pathophysiology, diagnostics, monitoring, and treatment in different age groups. More importantly, promising areas of investigation that may lead to optimal outcomes for patients afflicted with this lifelong, systemic disease were discussed with a research agenda proposed for the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据